Evidence map›Paper›PMID 36387126›Full record

ArticleFrontiers in oncology2022

Case Report:

Tianyue Li, Xiaojing Jiang, Zhaoqi Zhang, Xiaolin Chen, Jianfang Wang, Xinming Zhao, Jingmian Zhang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. The Role ofMolecular imaging and radionuclide therapy · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tianyue LiDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xiaojing JiangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhaoqi ZhangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xiaolin ChenDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jianfang WangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xinming ZhaoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jingmian ZhangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hebei Medical University · CNFourth Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common malignant tumor in adult women. Its common metastatic sites are lymph nodes, bones, lungs, the liver, and the brain. It is so rare for a patient with breast cancer to have metastases of the gastrointestinal tract, peritoneum, and ovary at the same time that the clinical reporting rate is low. We present a case of a 61-year-old woman who underwent right mastectomy and chemoradiotherapy 3 years ago because of mixed invasive ductal-lobular breast cancer. This time, she came to the hospital due to the symptom of stomach discomfort for 2 weeks. The gastroscopy biopsy result showed gastric metastasis from breast cancer. Then,

Indexed as

18F-FDG68Ga-FAPIbreast cancergastric metastasisovarian metastasisperitoneal carcinomatosisPET/CT

Identifiers

PMID36387126
PMCPMC9643837
OpenAlexW4307553473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.